Aspects affecting quality of life in patients with multiple sclerosis

Czech version

Authors: I. Šrotová; V. Benetinová; M. Hladíková; M. Petrášová
Authors‘ workplace: Neurologická klinika LF MU a FN Brno
Published in: Cesk Slov Neurol N 2025; 88(4): 243-248
doi: https://doi.org/10.48095/cccsnn2025243

Overview

Multiple sclerosis is a chronic autoimmune disease with elements of neurodegeneration typically affecting young adults of working age. Although the disease is currently very well amenable to therapeutic intervention, it is still not definitively curable and the patient is left to deal with the chronic nature of the disease for the rest of his/her life. Currently, thanks to modern therapies, we are trying to maintain the clinical and radiological stability of the disease. At the same time, however, it is also necessary to take into account the fact that the focus should not be “only” on the disease itself, but primarily on the patient who is living with the disease. This is why the term “quality of life” (QoL) is increasingly being heard across the spectrum of medical specialties, and the concern to increase or maintain the level of QoL is reflected in the therapeutic approach. At the same time, early diagnosis and treatment of potential comorbidities that are closely related to MS and may contribute to reduced QoL is important. The ability to assess the patient‘s condition –⁠ both clinically and biopsychosocially –⁠ is a prerequisite for early identification of risk factors and implementation of appropriate interventions leading to improvement or maintenance of QoL.

Keywords:

Quality of life – Multiple sclerosis – Fatigue – cognitive dysfunction – evaluation of quality of life

Sources

1. Dobson R, Giovannoni G. Multiple sclerosis –⁠ a review. Eur J Neurol 2019; 26(1): 27–40. doi: 10.1111/ene.13819.

2. Haraldstad K, Wahl A, Andenæs R et al. A systematic review of quality of life research in medicine and health sciences. Qual Life Res 2019; 28(10): 2641–2650. doi: 10.1007/s11136-019-02214-9.

3. Yin S, Njai R, Barker L et al. Summarizing health-related quality of life (HRQOL): development and testing of a one-factor model. Popul Health Metr 2016; 14 : 22. doi: 10.1186/s12963-016-0091-3.

4. Bech P. Rating scales for psychopathology, health status and quality of life. A compendium on documentation in accordance with the DSM-III-R and WHO systems. Berlin: Springer; 1993 : 468–469.

5. Piťha J. Kvalita života pacientů s roztroušenou sklerózou ve světle klinických studií. Remedia 2016; 27.

6. Gompertz P, Harwood R, Ebrahim S et al. Validating the SF-36. BMJ 19; 305(6854): 645–646. doi: 10.1136/bmj.305.6854.645-c.

7. Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992; 30(6): 473–483.

8. Balestroni G, Bertolotti G. L’EuroQol-5D (EQ-5D): uno istrumento per la misuradella qualità della vita [EuroQol-5D (EQ-5D): an instrument for measuring quality of life]. Monaldi Arch Chest Dis 2012; 78(3): 155–159. doi: 10.4081/monaldi.2012.121.

9. Bergner M, Bobbitt RA, Kressel S et al. The sickness impact profile: conceptual formulation and methodology for the development of a health status measure. Int J Health Serv 1976; 6(3): 393–415. doi: 10.2190/RHE0-GGH4-410W-LA17.

10. Carlsson M, Hamrin E. Measurement of quality of life in women with breast cancer. Development of a Life Satisfaction Questionnaire (LSQ-32) and a comparison with the EORTC QLQ-C30. Qual Life Res 1996; 5(2): 265–274. doi: 10.1007/BF00434748.

11. Skevington SM, Lotfy M, O’Connell KA et al. The World Health Organization’s WHOQOL-BREF quality of life assessment: psychometric properties and results of the international field trial. A report from the WHOQOL group. Qual Life Res 2004; 13(2): 299–310. doi: 10.1023/B.0000018486.91360.00.

12. Kaplan RM, Anderson JP, Wu AW et al. The Quality of Well-being Scale. Applications in AIDS, cystic fibrosis, and arthritis. Med Care 1989; 27 (3 Suppl): S27–S43. doi: 10.1097/00005650-198903001-00003.

13. Majerníková Ľ, Hudáková A, Obročníková A. Psychometrická validácia dotazníka MSQOL-54 na Slovensku –⁠ pilotná štúdia. Cesk Slov Neurol N 2023; 86(4): 262–270. doi: 10.48095/cccsnn2023262.

14. Gil-González I, Martín-Rodríguez A, Conrad R et al. Quality of life in adults with multiple sclerosis: a systematic review. BMJ Open 2020; 10(11): e04124. doi: 10.1136/bmjopen-2020-041249.

15. Sabanagic-Hajric S, Suljic E, Memic-Serdarevic A et al. Quality of life in multiple sclerosis patients: influence of gender, age and marital status. Mater Sociomed 2022; 34(1): 19–24. doi: 10.5455/msm.2022.33.19-24.

16. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983; 33(11): 1444–1452. doi: 10.1212/wnl.33.11.1444.

17. Rezapour A, Almasian Kia A, Goodarzi S et al. The impact of disease characteristics on multiple sclerosis patients’ quality of life. Epidemiol Health 2017; 39: e2017008. doi: 10.4178/epih.e2017008.

18. Milinis K, Tennant A, Young CA. Spasticity in multiple sclerosis: associations with impairments and overall quality of life. Mult Scler Relat Disord 2016; 5 : 34–39. doi: 10.1016/j.msard.2015.10.007.

19. Gross HJ, Watson C. Characteristics, burden of illness, and physical functioning of patients with relapsing-remitting and secondary progressive multiple sclerosis: a cross-sectional US survey. Neuropsychiatr Dis Treat 2017; 13 : 1349–1357. doi: 10.2147/NDT. S132079.

20. Šťastná D, Menkyová I, Horáková D. Progresivní roztroušená skleróza ve světle nejnovějších poznatků. Cesk Slov Neurol N 2023; 86(1): 10–17. doi: doi: 10.48095/cccsnn202310.

21. Rojas JI, Carnero Contentti E, Alonso R et al. Burden of treatment and quality of life in relapsing remitting multiple sclerosis patients under early high efficacy therapy in Argentina: data from the Argentinean registry. Mult Scler Relat Disord 2024; 85 : 105543. doi: 10.1016/j.msard.2024.105543.

22. Fernández O, Fernández V, Baumstarck-Barrau K et al. MusiQoL study group of Spain. Validation of the Spanish version of the Multiple Sclerosis International Quality of Life (MusiQoL) questionnaire. BMC Neurol 2011; 11 : 127. doi: 10.1186/1471-2377-11-127.

23. Miertová M, Juríčková N, Ovšonková A. Bolesť u pacientov s roztrúsenou sklerózou a jej vplyv na vybrané aspekty kvality života. Cesk Slov Neurol N 2024; 87(3): 208–212. doi: 10.48095/cccsnn2024208.

24. Oliva Ramirez A, Keenan A, Kalau O et al. Prevalence and burden of multiple sclerosis-related fatigue: a systematic literature review. BMC Neurol 2021; 21(1): 468. doi: 10.1186/s12883-021-02396-1.

25. Muir-Nash J, Steinberg AD. The fatigue severity scale: application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol 1989; 46(10): 1121–1123. doi: 10.1001/archneur.1989.00520460115022.

26. Fisk JD, Pontefract A, Ritvo PG et al. The impact of fatigue on patients with multiple sclerosis. Can J Neurol Sci 1994; 21(1): 9–14. doi: 10.1017/S0317167100048691.

27. Flachenecker P, Kümpfel T, Kallmann B et al. Fatigue in multiple sclerosis: a comparison of different rating scales and correlation to clinical parameters. Mult Scler 2002; 8(6): 523–526. doi: 10.1191/1352458502ms839oa.

28. Scott J, Huskisson EC. Graphic representation of pain. Pain 1976; 2(2): 175–184.

29. Aboud T, Schuster NM. Pain Management in multiple sclerosis: a review of available treatment options. Curr Treat Options Neurol 2019; 21(12): 62. doi: 10.1007/s11940-019-0601-2.

30. Tur C. Fatigue management in multiple sclerosis. Curr Treat Options Neurol 2016; 18(6): 26. doi: 10.1007/s11940-016-0411-8.

31. Natsheh JY, DeLuca J, Costa SL et al. Methylphenidate may improve mental fatigue in individuals with multiple sclerosis. Mult Scler Relat Disord 2021; 56 : 103273. doi: 10.1016/j.msard.2021.103273.

32. Thomas S, Learmonth YC, Sandroff BM et al. Comparative effectiveness of cognitive behavioural therapy, modafinil, and their combination for treating fatigue in multiple sclerosis (COMBO-MS): a randomised, statistician-blinded, parallel-arm trial. Lancet Neurol 2024; 23(10): 1015–1026. doi: 10.1016/S1474-4422(24) 30201-5.

33. Benedict RHB, Amato MP, DeLuca J et al. Cognitive impairment in multiple sclerosis: clinical management, MRI, and therapeutic avenues. Lancet Neurol 2020; 19(10): 860–871. doi: 10.1016/S1474-4422(20)30277-5.

34. Pitteri M, Romualdi C, Magliozzi R et al. Cognitive impairment predicts disability progression and cortical thinning in MS: an 8-year study. Mult Scler 2017; 23(6): 848–854. doi: 10.1177/1352458516665496.

35. Papathanasiou A, Messinis L, Georgiou VL et al. Cognitive impairment in relapsing remitting and secondary progressive multiple sclerosis patients: efficacy of a computerized cognitive screening battery. ISRN Neurol 2014; 2014 : 151–159. doi: 10.1155/2014/151379.

36. Bergmann C, Becker S, Watts A et al. Multiple sclerosis and quality of life: the role of cognitive impairment on quality of life in people with multiple sclerosis. Mult Scler Relat Disord 2023; 79 : 104966. doi: 10.1016/j.msard.2023.104966.

37. Munger KC, Martinez AP, Hyland MH. The impact of cognitive rehabilitation on quality of life in multiple sclerosis: a pilot study. Mult Scler J Exp Transl Clin 2021; 7(3): 20552173211040239. doi: 10.1177/20552173211040239.

38. Beiske AG, Svensson E, Sandanger I et al. Depression and anxiety amongst multiple sclerosis patients. Eur J Neurol 2008; 15(3): 239–245. doi: 10.1111/j.1468-1331.2007.02041.

39. Mezerová V, Meluzínová E, Poušek L. Kvalita života pacientů s roztroušenou sklerózou mozkomíšní. Neurol Praxi 2014; 15(2): 97–100.

40. McCabe MP, Stojanovska M, Yucel M et al. Quality of life and multiple sclerosis: the role of psychosocial factors. BMC Neurol 2022; 22(1): 258. doi: 10.1186/s12883-022-02747-2.

41. Rieckmann P, Centonze D, Elovaara I. Social factors impacting quality of life in MS. Springer Neuropsychology 2021; 45(2): 65–72. doi: 10.1007/s00415-021-10423-8.

42. MS Brain Health Initiative. Social determinants of health: impact on multiple sclerosis outcomes. MS Brain Health Published 2023. [online]. Available from: https://www.msbrainhealth.org.